April 3, 2020 – Evolva is pleased to announce that the first findings of the much-anticipated RESHAW (Resveratrol Supporting Healthy Aging in Women) clinical study have been peer-reviewed and published in Nutrients. The report, “Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women,” is the first of a series of anticipated publications from the extensive two-year RESHAW clinical trial of Veri-te™ resveratrol in 125 postmenopausal women.
Conducted in Australia by Dr. Rachel Wong, Jay Jay Thaung Zaw and Emeritus Professor Peter Howe at the University of Newcastle’s Clinical Nutrition Research Centre, RESHAW is the largest, longest-running study of its kind with resveratrol. Supported by the National Health and Medical Research Council and the Australian Research Council (NHMRC-ARC) and a grant from Evolva, RESHAW was designed to investigate the impact of resveratrol supplementation on cognitive performance, along with a wide range of secondary outcomes, including body composition and perceptions of wellbeing, physical function, and pain.
In the crossover comparison, volunteers were randomized to take two capsules containing 75mg of Evolva’s Veri-te™ resveratrol ingredient daily or a matching placebo supplement for 12 months, followed by the alternate treatment for a further 12 months. “Our observed improvement in overall cognitive performance with resveratrol (d= 0.18) could potentially reverse cognitive ageing by up to 10 years” in postmenopausal women, commented NHMRC-ARC Dementia Research Fellow Dr. Wong. “We observed an improvement in overall cognitive performance which appeared to be due to improvements in processing speed and cognitive flexibility,” said Dr. Wong, “which are critical to supporting executive function in the aging population.”
“This momentous publication from the team at the University of Newcastle highlights the benefits that Veri-te™ resveratrol can have on brain health, making resveratrol an essential ingredient for postmenopausal women and healthy aging,” said Clare Panchoo, VP, Health Ingredients, Evolva. “This first peer-reviewed publication from the RESHAW clinical study provides the evidence that supplementation with Veri-te™ resveratrol should be a key strategy for the design and delivery of effective supplements that may attenuate the decline in brain health as women age and improve overall wellbeing post-menopause,” said Panchoo.
The evidence in this first report “confirms our previous observations in both men and women that a regular low dose of resveratrol can sustain cerebrovascular function, which has helped to preserve cognitive function, particularly in the more elderly women,” according to Prof Howe. “Most importantly, it shows that these benefits are not short-lived but can be sustained with ongoing supplementation for at least 12 months,” said Prof Howe.
Panchoo adds that “our customers have been anticipating the results from RESHAW and have already initiated new product development based on this first publication; we further expect the positive outcomes to drive sales of Veri-te™ resveratrol globally.”
About Veri-te™ resveratrol
Veri-teTM resveratrol offers customers a guarantee of quality together with strong scientific backing and versatility in application, which can both inspire and enable customers to develop innovative and award-winning products. www.veriteresveratrol.com
Evolva is a Swiss biotech company focused on the research, development and commercialization of products based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at www.evolva.com.